https://www.PR.com/ Latest news releases from PR.com for NuvOx Therapeutics. Thu, 21 May 2026 09:35:59 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/931445 Fri, 14 Feb 2025 03:00:00 -0500 NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). This acceptance will enable the company to commence the Phase IIb NOVEL trial (NanO2 in Large VessEL Occlusion Stroke (NOVEL): a multicentre [PR.com] https://www.pr.com/press-release/931445 NuvOx Therapeutics https://www.pr.com/press-release/924092 Thu, 31 Oct 2024 03:00:00 -0400 Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine efforts to publish 2 journal articles that help explain how the NuvOx drug candidate - NanO2TM works. Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic, an article that explains NanO2’s mechanism of action of delivering oxygen. The British Journal of Cancer Research published A Phase 2 [PR.com] https://www.pr.com/press-release/924092 NuvOx Therapeutics https://www.pr.com/press-release/920614 Sat, 21 Sep 2024 08:54:58 -0400 NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced that it has received a Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medicinal Products Manufactured outside of EU (in Third Countries) . This declaration fulfills a key requirement to initiate the NOVEL clinical trial (“NanO2 in Large VessEL Occlusion Stroke”). [PR.com] https://www.pr.com/press-release/920614 NuvOx Therapeutics https://www.pr.com/press-release/915613 Fri, 12 Jul 2024 03:00:00 -0400 NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress Syndrome (ARDS) has been an important part of our overall development strategy. We recently expanded our protocol inclusion criteria [PR.com] https://www.pr.com/press-release/915613 NuvOx Therapeutics https://www.pr.com/press-release/903733 Sun, 14 Jan 2024 12:50:16 -0500 NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” [PR.com] https://www.pr.com/press-release/903733 NuvOx Therapeutics https://www.pr.com/press-release/897266 Wed, 11 Oct 2023 13:22:52 -0400 NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Fundable Companies® List. NuvOx Therapeutics competed against over 3,000 of early-stage US companies to be named one of 17 companies in total. [PR.com] https://www.pr.com/press-release/897266 NuvOx Therapeutics https://www.pr.com/press-release/896706 Wed, 27 Sep 2023 11:11:46 -0400 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In this raise, NuvOx leverages large angel groups nationwide, and 11 angel groups joined the round. As a result, NuvOx welcomes three board observers from New World Angels, NOLA Angel Network, and MEDA/TCA/Pasadena Angel Network. Evan Unger, MD, [PR.com] https://www.pr.com/press-release/896706 NuvOx Therapeutics https://www.pr.com/press-release/894791 Fri, 01 Sep 2023 03:00:00 -0400 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications. https://aacrjournals.org/cancerrescommun/article/3/8/1607/728499. Evan Unger, MD, President and CEO of NuvOx, said, “We are pleased that this article describing the results of our Phase Ib/IIa Glioblastoma (GBM) trial of [PR.com] https://www.pr.com/press-release/894791 NuvOx Therapeutics https://www.pr.com/press-release/888841 Fri, 09 Jun 2023 03:00:00 -0400 NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it enrolled and treated the first subject in the Phase IIb RESTORE Trial for newly-diagnosed glioblastoma multiforme (www.ClinicalTrials.gov: NCT03862430). Dr. Evan Unger, CEO and co-founder of NuvOx said, “We are thrilled to start [PR.com] https://www.pr.com/press-release/888841 NuvOx Therapeutics https://www.pr.com/press-release/884902 Mon, 24 Apr 2023 12:16:15 -0400 NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion [PR.com] https://www.pr.com/press-release/884902 NuvOx Therapeutics https://www.pr.com/press-release/880576 Thu, 02 Mar 2023 03:00:00 -0500 NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it has been issued US Patent No. 11,571,467, “Dodecafluoropentane emulsion (DDFPe) as a stroke and ischemia therapy.” The issued patent has claims for methods of use of DDFPe for stroke treatment as well as claims covering the use of [PR.com] https://www.pr.com/press-release/880576 NuvOx Therapeutics https://www.pr.com/press-release/869924 Thu, 22 Sep 2022 03:00:00 -0400 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Katy Peters to its Scientific Advisory Board (SAB). Dr. Katy Peters, MD, Ph.D. FAAN is an associate professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. Her academic medical career started at Stanford [PR.com] https://www.pr.com/press-release/869924 NuvOx Therapeutics https://www.pr.com/press-release/861616 Thu, 19 May 2022 09:58:40 -0400 NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” [PR.com] https://www.pr.com/press-release/861616 NuvOx Therapeutics https://www.pr.com/press-release/861001 Wed, 11 May 2022 03:00:00 -0400 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’ experiences in various biopharmaceutical and device/diagnostic companies. With hands on experience in all aspects of drug [PR.com] https://www.pr.com/press-release/861001 NuvOx Therapeutics https://www.pr.com/press-release/859633 Tue, 19 Apr 2022 13:34:03 -0400 NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. [PR.com] https://www.pr.com/press-release/859633 NuvOx Therapeutics https://www.pr.com/press-release/859467 Sun, 17 Apr 2022 03:00:00 -0400 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. [PR.com] https://www.pr.com/press-release/859467 NuvOx Therapeutics https://www.pr.com/press-release/856377 Sat, 05 Mar 2022 03:00:00 -0500 On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a translational research program aiming to develop the Company’s drug, NanO2™ in combination with immunotherapy treatment of [PR.com] https://www.pr.com/press-release/856377 NuvOx Therapeutics https://www.pr.com/press-release/854814 Fri, 11 Feb 2022 03:00:00 -0500 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be leveraging One on One Partnering platform by BIO to meet investment communities, fellow biotech companies, as well as service [PR.com] https://www.pr.com/press-release/854814 NuvOx Therapeutics https://www.pr.com/press-release/852929 Fri, 14 Jan 2022 03:00:00 -0500 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in the H.C. Wainwright Bioconnect Virtual Conference and the Access China Biotech Forum on behalf of NuvOx. In addition, the [PR.com] https://www.pr.com/press-release/852929 NuvOx Therapeutics https://www.pr.com/press-release/846423 Tue, 12 Oct 2021 05:00:00 -0400 NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. STTR programs are highly competitive programs that encourage domestic small businesses to engage in Federal Research/Research and Development (R/R&D) with the potential for [PR.com] https://www.pr.com/press-release/846423 NuvOx Therapeutics https://www.pr.com/press-release/844212 Thu, 09 Sep 2021 05:00:00 -0400 NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of breast cancer affecting about 50,000 patients each year in the US. It is particularly common in African American women. NanO2 [PR.com] https://www.pr.com/press-release/844212 NuvOx Therapeutics https://www.pr.com/press-release/841291 Thu, 29 Jul 2021 04:00:00 -0400 NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this country, the #1 cause of long-term disability, and the #1 cause of expense for long-term medical care. Evan Unger, MD, CEO of [PR.com] https://www.pr.com/press-release/841291 NuvOx Therapeutics https://www.pr.com/press-release/841135 Fri, 23 Jul 2021 03:00:00 -0400 NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing a new method of treating cancer utilizing Company’s lead drug candidate, NanO2TM, and its administration to reverse [PR.com] https://www.pr.com/press-release/841135 NuvOx Therapeutics https://www.pr.com/press-release/827635 Mon, 28 Dec 2020 16:35:45 -0500 NuvOx Pharma today announced that Jon S. Saxe has joined its Board of Directors. Saxe brings to NuvOx many years of experience from the biotechnology, pharmaceutical and venture capital industries. He has served as a director of more than 25 companies and currently is a director of several publicly traded biotechnology companies including Vistagen Therapeutics and DURECT Corporation as well as a number of private [PR.com] https://www.pr.com/press-release/827635 NuvOx Therapeutics https://www.pr.com/press-release/798557 Sun, 03 Nov 2019 03:00:00 -0500 NuvOx Pharma, Inc, a clinical stage biopharmaceutical company developing NanO2TM emulsion for oxygen delivery today announced the issuance of US Patent 10,456,468 – Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic. NanO2TM emulsion is designed to increase tumor oxygen levels to make tumors more sensitive to radiation therapy and chemotherapy, and the new patent covers the technology for these [PR.com] https://www.pr.com/press-release/798557 NuvOx Therapeutics https://www.pr.com/press-release/759278 Sat, 14 Jul 2018 03:00:00 -0400 Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx has received a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to fund the development of a new strategy to detect pancreatic cancer. The grant, 2R44CA203090-02, entitled “Thy-1 targeted microbubbles for early detection of pancreatic cancer,” is a joint project between NuvOx Pharma and the [PR.com] https://www.pr.com/press-release/759278 NuvOx Therapeutics https://www.pr.com/press-release/740118 Sat, 30 Dec 2017 03:00:00 -0500 NuvOx Pharma, a clinical stage biotechnology company, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that may allow quick preparation of an investigational drug for oxygen delivery. The drug, NVX-208, is injected intravenously then [PR.com] https://www.pr.com/press-release/740118 NuvOx Therapeutics https://www.pr.com/press-release/712551 Fri, 14 Apr 2017 03:00:00 -0400 The National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $317,743 for a study in pigs for NuvOx Pharma's drug, NVX-308, in heart attack. [PR.com] https://www.pr.com/press-release/712551 NuvOx Therapeutics https://www.pr.com/press-release/702882 Thu, 26 Jan 2017 09:18:57 -0500 NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. have signed a licensing agreement for the exclusive development and sales of NVX-408 for China for treating hemorrhagic shock and perioperative blood loss. NVX-408 is an oxygen therapeutic that is injected intravenously, flows through the lungs and picks up oxygen, then flows through the blood and passes hypoxic tissue then releases oxygen. Pre-clinical studies [PR.com] https://www.pr.com/press-release/702882 NuvOx Therapeutics https://www.pr.com/press-release/693737 Thu, 03 Nov 2016 03:00:00 -0400 NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, “B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant, said, "This project draws upon NuvOx’s expertise in nanotechnology to more specifically and effectively diagnose [PR.com] https://www.pr.com/press-release/693737 NuvOx Therapeutics https://www.pr.com/press-release/685149 Sat, 27 Aug 2016 03:00:00 -0400 NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, “Fibrin Targeted Microbubbles and Ultrasound for Treatment of Endocarditis.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant, said, “This [PR.com] https://www.pr.com/press-release/685149 NuvOx Therapeutics https://www.pr.com/press-release/684300 Mon, 22 Aug 2016 16:01:00 -0400 Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients. The trial will be performed at the University of Arkansas Medical System in Little Rock, Arkansas under the direction of Dr. William Culp, Jonathan Fitch Distinguished Chair in Stroke. Dr. Culp said, [PR.com] https://www.pr.com/press-release/684300 NuvOx Therapeutics https://www.pr.com/press-release/673136 Sat, 28 May 2016 03:00:00 -0400 Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer (STTR) grant is a joint development project between NuvOx and Stanford University. The two principal investigators on the project [PR.com] https://www.pr.com/press-release/673136 NuvOx Therapeutics https://www.pr.com/press-release/658174 Sun, 14 Feb 2016 03:00:00 -0500 Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves excruciating, debilitating, episodic pain and can contribute to contribute to [PR.com] https://www.pr.com/press-release/658174 NuvOx Therapeutics https://www.pr.com/press-release/657965 Sat, 13 Feb 2016 03:00:00 -0500 The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves excruciating, debilitating, episodic pain and can contribute to contribute to infection, stroke, multisystem organ [PR.com] https://www.pr.com/press-release/657965 NuvOx Therapeutics https://www.pr.com/press-release/649401 Mon, 07 Dec 2015 13:53:16 -0500 Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-108 for treatment of Glioblastoma. Orphan status provides NuvOx with development and commercial incentives such as tax credits for qualified clinical testing and market exclusivity for 7 years after the marketing approval is granted. [PR.com] https://www.pr.com/press-release/649401 NuvOx Therapeutics